Immuno-Oncology Strategic Industry Research Report 2023-2024 & 2030: Approval of Pembrolizumab (Keytruda) and Nivolumab (Opdivo), which Target PD-1 and PD-L1 Pathways have Set New Benchmarks
05. Dezember 2024 10:16 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Immuno-Oncology...
Cancer Immunotherapy Strategic Research Business Report 2023-2030: Improved Delivery Systems, Desire for Non-Toxic Treatments, Checkpoint Inhibitors Spur New Developments and Growth
04. Dezember 2024 10:55 ET
|
Research and Markets
Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Cancer...
Cancer Immunotherapy Drug Discovery Outsourcing Strategic Business Report 2024: Global Market to Reach $4 Billion by 2030, Driven by Trends in Global Expansion to Tap into Emerging Markets
02. Dezember 2024 07:32 ET
|
Research and Markets
Dublin, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The...
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
08. November 2024 14:51 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers
Cancer Immunotherapy Market Research 2024-2032: Personalized Cancer Vaccines and CAR T Cell Therapy Revolutionize Immunotherapy
07. Oktober 2024 07:18 ET
|
Research and Markets
Dublin, Oct. 07, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report, Forecast by Products, Application, End Users, Countries and Company Analysis, 2024-2032" report has been added to ...
Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027
19. September 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17. September 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
India Liver Cancer Therapeutics Research Report 2024-2030 Featuring Natco Pharma, Dr. Reddy's Laboratories, Intas Pharmaceuticals, Mylan Pharmaceuticals, Lupin, Biocon, and Hetero Labs
11. September 2024 11:54 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Liver Cancer Therapeutics Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ...
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
24. Juli 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
Global Cancer Immunotherapy Market Report 2024, with Revenue Forecasts to 2034 for Five Regional and 25 Key National Markets
27. Juni 2024 07:02 ET
|
Research and Markets
Dublin, June 27, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Cancer Immunotherapy Market is...